Spruce Biosciences (SPRB) is nearing pivotal data releases from its ongoing clinical trials of Tildacerfont, an investigational therapy for Congenital Adrenal Hyperplasia.
Tildacerfont is a non-steroidal, oral second-generation CRF1 receptor antagonist, being developed to treat patients with classic congenital adrenal hyperplasia (CAH) and other diseases characterized by elevated levels of adrenocorticotropic hormone.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com